

## Ian B. Edvalson

PARTNER

Technology  
Transactions  
*Palo Alto*

iedvalson@wsgr.com  
650-849-3395



## FOCUS AREAS

Biotech  
Global Generics  
Life Sciences  
Technology Transactions

## HIGHLIGHTS

- Technology Transactions Veteran**  
Ian has nearly 30 years of business and legal experience representing life sciences clients in strategic alliances, agreements, arrangements, collaborations, and joint ventures.
- Prominent Life Sciences and Medtech Clients**  
Ian has represented numerous well-known life sciences and medtech companies, including Illumina, Mylan, Pfenex, and Zymeworks.
- A Recognized Practitioner**  
Ian has been recognized as a leader in his field by *Chambers USA*.

## EXPERIENCE

Ian Edvalson is a technology transactions partner in Wilson Sonsini Goodrich & Rosati's Palo Alto office and a former member of the firm's board of directors. Ian advises numerous domestic and international public and private biopharmaceutical, medtech, and life sciences companies with all of the transactions related to the discovery, development, supply, and commercialization of their products, technologies, and services. He counsels clients with respect to the structuring and negotiating of a wide range of arrangements designed to maximize the value of their businesses.

Ian specializes in working with his clients on the most complex strategic alliances and joint ventures for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements.

Ian draws on his almost 30 years of business and legal experience (including his time leading the corporate and business development functions at Third Wave Technologies, a public genomics company) to address the full range of issues and transactions facing biopharmaceutical, medtech, and life sciences companies. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

## CREDENTIALS

### Education

- J.D., University of Chicago Law School
- B.S., Molecular Biology, Brigham Young University
- B.A., Korean, Brigham Young University

## Honors

- Named in the 2007-2017 and 2021-2025 editions of *Chambers USA: America's Leading Lawyers for Business*
- Named in *Northern California Super Lawyers* in 2011, 2013, 2014, and 2015

## Admissions

- State Bar of California

## MATTERS

---

### Illustrative Representations

- **ABL Bio** in its exclusive collaboration and worldwide license agreement with **SANOFI**
- **Armagen** in its collaboration with **Shire** for treatments of Hunter Syndrome
- **Astellas** in its joint venture with **CVC Investments**
- **Biomarin** in its joint venture with **Sanofi** (Genzyme)
- **Caribou Biosciences** in its co-founding and licensing of **Intellia Therapeutics** for therapeutic products based on CRISPR-Cas technologies and cross-license with **DuPont** for foundational CRISPR-Cas technologies and products
- **Cytopia** in its research and license arrangement with **Novartis** for JAK3 products
- **Durect** in its license with Gilead for long-acting HIV, HBV, and HVC products, asset transfer arrangement with **Impax Laboratories** for Eladur, and in its alliance with **Santen** for a sustained-release SABER ophthalmology product
- **Gilead Sciences** in its acquisition of YM Biosciences and in its license from **Theraclone** for its broadly neutralizing HIV antibodies
- **Illumina** in its license and supply arrangement with **Natera** for certain diagnostic products and technologies
- **Mesoblast** in various strategic alliances including with **Grunenthal**, **Lonza**, **JCR**, and **Tasly** for its cell therapy products
- **Mylan** in various strategic alliances including with **Biocon** for various biosimilar products and with **Pfizer** for the commercialization of EpiPen, multiple generic products for Japan, and development and commercialization of proprietary inhalable products
- **Pacific Biosystems** in its acquisition by **Illumina** and its collaboration with **F. Hoffman-La Roche** for specific diagnostic products and platforms
- **Parvus Therapeutics** in its collaborations with **Roche/Genentech** and **Novartis** for its tolerogenic nanoparticle products
- **Pfenex** in its worldwide marketing arrangement with **Alvogen**, its joint venture with **Agila Biotech** for various biosimilar products and in its license and option transaction with **Jazz Pharmaceuticals** for hematological malignancy products
- **Schiff Nutrition** in its acquisition of **Ganrden Biotech**
- **Shin Nippon Biomedical Laboratories** in its license with **Transcept** for a nasally-delivered DHE product
- **Taiho Pharmaceuticals** in its licenses with **PharmaMar** for Yondelis and with **Teva** for Actiq
- **Tolero Pharmaceuticals** in its acquisition by **Sumitomo Dainippon Pharmaceuticals** and licenses with **Sanofi** and **Mannkind**
- **Verily Life Sciences** in its collaborations with **Dexcom** and **Proctor & Gamble**
- **Y's Therapeutics** in its acquisition of certain assets from **Thios Pharmaceuticals**
- **Zymeworks** in its strategic alliances with **Celgene**, **Eli Lilly**, **Glaxo SmithKline**, and **Merck** to design, develop, and commercialize proprietary bi-specific antibodies

## INSIGHTS

---

### Select Speaking Engagements

- “Building Successful Corporate Partnerships,” HealthTech Conference
- “The Challenges of Pharma and Biotech in Emerging Markets—Focus on China and India,” AusBiotech
- “Where does Biopharma go from here?” EPPIC Annual Conference
- “Licensing Strategies—Views from the Trenches,” The Bio2Device Group